ライフサイエンスコーパス: CLIA

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 l Laboratory Improvement Amendments of 1988 (CLIA) to promote uniform quality and standards among all

2 e their tumor tested for KRAS mutations in a CLIA-accredited laboratory.

3 mic DNA was tested for the KRAS-variant in a CLIA-certified laboratory.

4 or wider availability of therapies, IGP in a CLIA-framework is feasible and valuable in selection/pri

5 perform Clinical Laboratory Improvement Act (CLIA) default QC.

6 ing to Clinical Laboratory Improvements Act (CLIA) guidelines for laboratory-developed tests (LDTs).

7 linical Laboratories Improvement Amendments (CLIA) and their continuing impact on physician office la

8 linical Laboratories Improvement Amendments (CLIA) and their impact of office practice.

9 Clinical Laboratory Improvement Amendments (CLIA) compliant setting enables a single assay to provid

10 Clinical Laboratory Improvement Amendments (CLIA) criterion for uric acid analysis (+/-17%).

11 Clinical Laboratory Improvement Amendments (CLIA) environment.

12 Clinical Laboratory Improvement Amendments (CLIA)-approved CLSI standard agar dilution method and, s

13 Clinical Laboratory Improvement Amendments (CLIA)-waived setting in comparison to bacterial culture

14 ibody absorption, microhemagglutination, and CLIA was 87.5%, 91.7% and 100%, respectively.

15 ugh director responsibilities are defined by CLIA legislation, there is no standardization of job des

16 However, only this newly developed CLIA test showed high specificity and correlated with th

17 cificity and intermediate thresholds (ELISA, CLIA), high-dose heparin confirmation step (ELISA), and

18 new sandwich chemiluminescence immunoassay (CLIA) combining an Affimer with a monoclonal antibody (A

19 ation test, a chemiluminescence immunoassay (CLIA), and a Treponema pallidum particle agglutination (

20 wed by a VlsE chemiluminescence immunoassay (CLIA); and (3) a variable major protein-like sequence, e

21 , polyspecific chemiluminescent immunoassay (CLIA) with a high threshold, and immunoglobulin G (IgG)-

22 This study indicates that Affimer-MAb CLIA can be used to generate a sensitive immunodiagnosti

23 imer with a monoclonal antibody (Affimer-MAb CLIA).

24 The proposed CLIA assay demonstrated a wide linear range 0.03-600 ng/

25 reshold, and immunoglobulin G (IgG)-specific CLIA with low threshold.

26 ts with high thresholds (ELISA; IgG-specific CLIA), combination of IgG specificity and intermediate t

27 The CLIA and TP-PA results were 100% concordant.

28 e first full year of compulsory PT under the CLIA regulations based on the type of testing facility p

29 ration as a component of compliance with the CLIA regulations were obtained.

30 ns for WGS applications in PHLs according to CLIA guidelines, (ii) the development of quality assuran

31 Median time to CLIA-validated results was 116 days with CLIA-validation

32 fractory cancer patients was conducted using CLIA-compliant IGP.

33 ajor protein-like sequence, expressed (VlsE) CLIA followed by a C6 EIA.

34 to CLIA-validated results was 116 days with CLIA-validation of targets achieved in 21/22 patients.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。